Zynerba Pharmaceuticals (ZYNE): Why ZYNE going way higher. FRAGILE X CBD...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	185
Posts	2462
Boards Moderated	0
Alias Born	02/10/2017

Fress

Re: None

Wednesday, 05/15/2019 7:57:37 AM

Wednesday, May 15, 2019 7:57:37 AM

Why ZYNE going way higher. FRAGILE X CBD GEL Phase 2 showed 55% improvement by week-12, improved by 75% 12months.Fragile FX no FDA drug +Autism & epilepsy n PH3.

Deep pipeline focused on high unmet medical needs; translating
into multi-billion dollar market opportunity with Zygel™
• Four clinical shots on goal: FXS, DEE, ASD, 22q
• Experienced team
• Proven development and commercialization track record in transdermal
delivery, orphan diseases, neurology, psychiatry
• Well capitalized No Debt
• Cash runway expected into the first quarter of 2021 - beyond the
planned NDA filing and potential approval in FXS
• Multiple expected near term milestones

April Presentation:
http://ir.zynerba.com/static-files/e772c9c3-7f37-4f0b-8844-d5a5e601cbf3

ZYNE Pipeline
https://zynerba.com/in-development/

Patented Biosynthetic Manufacturing
https://zynerba.com/our-focus/why-pharmaceutical-manufacturing/

GWPH 5.6 Billion Market Cap
ZYNE 280 Million Market Cap

$ZYNE